diopathic dilated cardiomyopathy (DCM) is primarily a heart muscle disease characterized by left ventricular dilatation and depressed myocardial contractility with secondary diastolic dysfunction, resulting in progressive refractory congestive heart failure. Although inherited gene defects account for 25-30% of DCM cases, 1,2 most cases are sporadic and consistent with multifactor genetic traits. 3-7 A number of modifier genes regulating the renin-angiotensin, sympathetic nervous, and neurohormonal systems might alter responses to drug therapy, 8 thereby potentially affecting the prognosis in patients with DCM. Given the importance of the adrenergic pathway in heart function, we elected to focus on adrenergic receptor-related genes that influence receptor function and synaptic norepinephrine release.
Heightened and sustained adrenergic stimulation plays an important pathophysiologic role in congestive heart failure, 9 which has an important impact on prognosis in patients with DCM. The sympathetic nervous system, especially through β1-adrenergic receptor (ADRB1) activation, appears to be of major importance not only in the genesis and/or progression of cardiac remodeling but also in induction of ventricular tachycardia. 10 Clinical evidence has accumulated regarding the beneficial effect of blockade of ADRB1 on cardiac remodeling and prognosis in patients with heart failure caused by DCM. 11 Two ADRB1 polymorphisms (Ser49Gly and Arg389Gly) have been widely studied. The Gly49 allele is associated with higher receptor activity and greater desensitization and downregulation via long-term stimulation. 12 This allele has been associated with better prognosis in patients with heart failure in some, but not all, studies. 13 The Arg389 allele has demonstrated higher coupling affinity and hyperactive signaling in experimental heart failure models, whereas the Gly389 allele shows increased downregulation, with a potentially protective role against adrenergic overstimulation. 12 The Arg389 allele has been reported
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to be associated with congestive heart failure 14 and ventricular tachycardia. 10 A second molecule, norepinephrine transporter (NET), plays an important role in cardiovascular homeostasis. More than 80% of norepinephrine is removed by presynaptic reuptake via NET. 15 The NET-182CC genotype has been reported to be resistant to β-blocker therapy. 16 We hypothesized that a combination of polymorphisms that result in increased synaptic norepinephrine release and enhanced receptor function would predispose patients with DCM to cardiovascular events. Therefore, we evaluated the effect of polymorphisms in the adrenergic receptor-related genes ADRB1 and NET on cardiovascular event-free survival in patients with DCM.
Methods

Study Population
Study protocols were approved by the Ethical Committee of Ehime University School of Medicine, and written and informed consent was obtained from each patient. In this study, 83 genetically unrelated Japanese patients with DCM were enrolled (64 males and 19 females; age 20 to 74 years; mean age at study entry, 59±14 years) between January 1999 and December 2003. All patients with DCM were diagnosed at Ehime University Hospital by 12-lead electrocardiography, transthoracic echocardiography, and cardiac catheterization. These patients also met the definition and classification proposed by the 1995 World Health Organization/International Society and the Federation of Cardiology Task Force. 17 The Figure 1 . The ADRB1 Ser49 carrier, 8 ADRB1 Arg389 carrier, 14 and NET-182CC genotype 16 were defined as the predicted risk genotypes. (A) No cardiovascular events occurred in patients with fewer than 2 predicted risk genotypes. (B) For the entire cohort, cardiovascular event-free survival was significantly poorer in patients with 3 predicted risk genotypes than in those with fewer than 3 predicted risk genotypes. Adrenergic-Related Polymorphisms and DCM exclusion criteria were as follows: (1) history of myocardial infarction; (2) history of alcohol abuse; (3) evidence of coronary heart disease or severe valvular heart disease by cardiac catheterization; and (4) active myocarditis state. At the time of entry, demographic information, previous cardiovascular evaluation, and medical therapy were recorded. Patients were prospectively followed-up to an endpoint of cardiovascular events between January 1999 and May 2004. Cardiovascular events were defined as cardiac death and emergent hospitalization as a result of congestive heart failure, arrhythmia, or cerebrovascular events. The duration of follow-up was defined as the interval from the date of enrollment to the date of the first cardiovascular event or last contact. Medical personnel in treatment and follow-up were blinded to the genotype status of individual subjects. Any previous cardiac studies in the patients were reviewed. All patients completed a standard questionnaire on personal medical history and family history.
Selection of Polymorphisms
Our aim was to identify the effect of polymorphisms in adrenergic receptor-related genes associated with cardiovascular events in patients with DCM. We searched published studies using the keywords "DCM", "adrenergic", "receptor", and "polymorphism", in the PubMed (NCBI) database. In addition, we selected the polymorphisms that had positive associations. As a result, we decided to analyze 2 candidate genes, ADRB1 and NET, which have been characterized and suggested to be associated with DCM.
Determination of Adrenergic Receptor-Related Genes Genotypes
Genomic DNA was extracted from peripheral blood samples with an extraction kit (Qiagen, Hilden, Germany) according to the manufacturer's protocol. The TaqMan chemical method was used to detect Ser49Gly (rs1801252) and Arg389Gly (rs1801253) in the ADRB1 gene (10q25.3) and T-182C (rs2242446) in the NET gene (16q12.2) as previously reported, with minor modifications. 18 The TaqMan SNP genotyping assays kit was used (Assay ID: C_ _ _8898508_10, C_ _ _8898494_10, and C_ _ 26354911_10). The fluorescence level of polymerase chain reaction products was measured with the ABI PRISM 7900HT Sequence Detection System (Applied Biosystems, Inc). The person who assessed the genotype was blinded to the clinical data of the patients from whom the samples originated.
Echocardiographic Study
M-mode and 2-dimensional echocardiography were performed in all patients via an SSD 870 or 9000 imaging system (Aloka, Tokyo, Japan) with a 2.5-or a 3.5-MHz transducer. From the M-mode echocardiographic study, the following conventional variables were measured according to the criteria of the American Society of Echocardiography: left ventricular dimensions at end-diastole and end-systole (LVDd and LVDs, respectively), and percent fractional shortening (FS).
Statistical Analysis
All statistical analyses were performed on a personal computer with SPSS Version 10.0 J for Windows (SPSS Inc, Chicago, IL, USA). Summary data are expressed as mean ± SD values. The differences in genotypes were analyzed by the chi-square test, which was also used to test deviations of genotype distri- 
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Outcomes: Cardiovascular Event-Free Survival
The median follow-up time for all patients was 45 months. During follow-up, 20 cardiovascular events occurred, including 6 cardiac deaths and 2 cerebral embolisms associated with new onset of atrial fibrillation. Figure 1A shows that no cardiovascular events occurred in patients with fewer than 2 predicted risk genotypes. For the entire cohort, cardiovascular event-free survival was significantly poorer in patients with 3 predicted risk genotypes than in those with fewer than 3 predicted risk genotypes (P=0.01, Figure 1B ). Cox regression analysis for patients with 3 predicted risk genotypes revealed an increased RR compared to those with fewer than 3 predicted risk genotypes (RR, 3.47; 95% CI, 1.25-9.62; P=0.017). Adjusting for age, age at disease onset, gender, FS, and B-type natriuretic peptide (BNP) in the overall model, the risk remained significant for patients with 3 predicted risk genotypes (adjusted RR, 3.57; 95% CI, 1.10-11.63; P=0.026). BNP plasma level was also a significant predictor (adjusted RR, 1.001; 95% CI, 1.000-1.002; P=0.008). 16 were defined as the predicted risk genotypes. Analyses were conducted on the basis of the number of predicted risk genotypes a patient carried. Adrenergic-Related Polymorphisms and DCM Table 1 shows baseline characteristics in 83 DCM patients. Table 2 (ADRB1 Ser49Gly), Table 3 (ADRB1 Arg389Gly), and Table 4 (NET T-182C) show the distribution of the observed genotype frequencies in this study. Frequencies of these genotypes were virtually identical to those predicted by Hardy-Weinberg equilibrium. No significant differences in the distribution of the ADRB1 Ser49Gly and Arg389Gly genotypes and alleles were observed between patients with and without cardiovascular events. No increase in risk with each ADRB1 gene polymorphism alone was observed. However, a significant difference in the distribution of the NET T-182C genotype between patients with and without cardiovascular events (P=0.04) was observed. Table 5 shows baseline patient characteristics according to predicted risk genotype. A significant difference in LVDd was observed among the genotype groups. In addition, trends in left atrial dimension (LAD) and BNP plasma levels were observed among the groups. Patients with 3 risk genotypes had a larger LVDd and LAD, and higher plasma levels of BNP than those without a 3-risk genotype (Figure 2) . Table 6 shows the relationship between the number of predicted risk genotypes and cardiovascular events. Overall, 56% of patients with 3 predicted risk genotypes experienced cardiovascular events. In contrast, patients with 1 predicted risk genotype experienced no cardiovascular events. A marked increase in the risk of cardiovascular events was observed among persons who had 3 predicted risk genotypes (P=0.03).
Frequency of Polymorphisms
Discussion
This study investigated the association between 3 variants in 2 candidate modifier genes of the adrenergic receptor-related genes previously implicated in the severity and progression of heart failure in patients with DCM. The possession of 3 predicted risk genotypes was associated with poorer cardiovascular event-free survival, which was the most remarkable finding in the present study. Early identification of genetic risk factors can have important clinical implications for risk stratification as well as the development of strategies for closer surveillance and intervention tailored to the individual's risk profile.
Functional Changes in ADRB1 and NET Polymorphisms
ADRB1 is encoded by an intronless gene located on chromosome 10q24-26, consisting of a short 5' untranslated region (UTR) of 86bp, an open reading frame that encodes a protein of 477 amino acids, and a 3' UTR of about 900 bp. 19 Ser49Gly and Arg389Gly are 2 major single nucleotide polymorphisms (SNP) in the ADRB1 gene. The Ser49Gly has been shown to confer differences in agonist-related downregulation, with the Ser49 variant being more resistant. 12 In addition, the Ser49 variant has also been shown to induce less active receptor coupling. 12 The Arg389 variant of ADRB1 has slightly higher basal and 3-4 -fold higher isoprenaline-stimulated adenylyl cyclase activity compared to the Gly389 variant, and it also desensitizes more rapidly. 12 These results provide good in vitro support for functional differences associated with both ADRB1 polymorphisms, but controversy remains regarding their in vivo impact.
The NET gene is located on chromosome 16q12 and contains 16 exons. The NET protein consists of 617 amino acids and has 12 transmembrane domains. 15 Non-synonymous SNP in the NET gene that influence transporter function can contribute to tachycardia. 15 In addition, the NET T-182C polymorphism has been associated with response to β-blockers; patients with the NET−182CC genotype are resistant to β-blocker therapy. 16 An allele frequency analysis demonstrated that the frequency of the ADRB1 Gly49 allele was 0.17, and was lower in Asians (0.14) than in Caucasians (0.12-0.16) and African Americans (0.23-0.28); the frequency of the ADRB1 Gly389 allele was 0.20, and was lower in Asians (0.20-0.30) than in Caucasians (0.24-0.34) and African Americans (0.39-0.46), and the frequency of the NET-182C allele was 0.41, and was higher in Asians (0.37-0.44) than in Caucasians (0.27) and African Americans (0.15). 11 The frequencies of these adrenergic-related polymorphisms were not significantly different from those previously reported in Japanese individuals. Therefore, these polymorphisms are unlikely to represent susceptibility genes for DCM.
Role of ADRB1 and NET Polymorphisms in Heart Failure
We hypothesized that ADRB1 and NET polymorphisms that resulted in increased synaptic norepinephrine release and enhanced receptor function would predispose patients with DCM to cardiovascular events. Although the myocardium response to a given level of adrenergic drive was shown to have the potential to be modified by adrenergic receptor genotype in previous studies, 20 little is known about the influence of this allele on sympathetic activation. ADRB1 Ser49 homozygotes have been reported to have a risk ratio of 2.34 for death or transplantation compared to those carrying Gly49 variants. 12 Although patients who were both homozygous for deletion (322-325) of the α2c receptor gene and homozygous for the ADRB1 Arg389 variant were reported to have a 10.11 -fold higher risk of heart failure, other studies suggested that the Arg389Gly polymorphism was neither a gene for susceptibility for DCM nor a genetic risk factor for the development of cardiac remodeling. 10,11 However, the compound effect of ADRB1-related gene polymorphisms might be larger than that of any individual ADRB1-related gene polymorphism, ie, having 3 predicted risk genotypes had a greater impact on disease progression than any individual ADRB1-related gene.
Study Limitations
The present study has a number of limitations. First, the as- sociation of these polymorphisms with heart failure susceptibility and prognosis is controversial. 11, 21 One possible reason for the inconsistencies between studies is the low sample numbers used, as in this study. The present results should be compared with those of larger studies. Second, the use of the combined endpoint of cardiac death or emergent hospitalization might not have been appropriate, as the timing of hospitalization can be influenced by multiple factors 22 and might not be equivalent to a cardiac "death". Third, this study did not assess the effect of genotype on circulating markers of either sympathetic activation or the renin-angiotensin system. Finally, although we examined the most common SNP in ADRB1 and NET, we cannot exclude the possibility that SNP in other candidate genes might be associated with cardiovascular events in patients with DCM. 4,11,23, 24 Further molecular and biological studies are required to clarify the relation between these polymorphisms and prognosis in patients with DCM. In addition, it might be important to determine whether there are racial differences in sympathetic activation and racial variations in the frequency of these polymorphisms.
In conclusion, genotyping at 3 loci might be a useful approach for identification of patients with DCM at risk for cardiovascular events.
